SUMMARY The concentration of hexosamine, a marker for mucin, was determined and related to the degree ofcholesterol saturation and to the occurrence of cholesterol crystals in gall bladder bile of gall stone patients (n=40) and gall stone free subjects (n=25). Ten of the gall stone patients had been treated with chenodeoxycholic acid (CDCA) and eight with ursodeoxycholic acid (UDCA) three to four weeks before cholecystectomy. The hexosamine content was significantly higher in gall stone patients (137 (19) ng/ml, mean (SE) than in gall stone free subjects (83 (9) ng/ml, p<002). Treatment with CDCA or UDCA decreased cholesterol saturation, but did not significantly affect the hexosamine concentration. There was no difference in hexosamine concentration between gall stone patients with and without cholesterol crystals. The results do not support the hypothesis that the degree of cholesterol saturation is important for the mucin content of gall bladder bile in man. Neither do the data indicate that the formation and occurrence of cholesterol crystals in gall bladder bile from gall stone patients is caused by an increased concentration of mucin. As the studies were conducted on patients who had already had gall stones for several years, however, an effect of mucin in the very early stage of gall stone formation cannot be completely excluded.
Supersaturated gall bladder bile is necessary for gall stone formation. On the other hand, many gall stone free subjects have saturated bile, and yet do not develop gall stones.'2 A key factor in the development of gall stones from supersaturated bile is the formation of cholesterol monohydrate crystals -that is, the nucleation process.`4 Holan et al' found that gall bladder bile from gall stone patients has considerably shorter nucleation time (mean of three days) than supersaturated bile from gall stone free subjects (mean of 15 days). Cholesterol crystal nucleation time thus provides a sharper discrimination between patients with cholesterol gall stones and gall stone free subjects than does cholesterol saturation.
The shorter nucleation time in gall stone patients 1506 may depend on the presence of nucleating factors, the deficiency of stabilising factors or an imbalance between factors which accelerate and inhibit the nucleation process. 4 On the basis of studies using animal models and in vitro experiments, several investigators have suggested that gall bladder mucin may play an important role as a nucleating factor."
Other authors have, however, questioned whether mucin is responsible for the rapid nucleation time in gall stone patients." 12 The aim of the present study was to determine the concentration of hexosamine, a marker for mucin, in gall bladder bile of gall stone free subjects and gall stone patients, and to correlate the findings with the cholesterol saturation and the occurrence of cholesterol crystals. Furthermore, the hexosamine concentration was determined in gall stone patients pretreated with chenodeoxycholic acid (CDCA) or ursodeoxycholic acid (UDCA), bile acids known to make gall bladder bile unsaturated with cholesterol and thus capable to induce gall stone dissolution.
Methods

PATIENTS
The study comprised 25 gall stone free subjects and 40 patients undergoing cholecystectomy because of cholesterol gall stones. They were all non-obese (relative body weight less than 125%) and normo Chenodeoxycholic acid and UDCA were administered in a daily dose of 15 mg/kg body weight for three to four weeks before operation. The medication was well tolerated. Most of the subjects treated with CDCA noted softer stools, and two developed occasional diarrhoea. Body weights remained unchanged.
About two to three days before surgery, the patients were hospitalised and given the regular hospital diet, in which 30, 20, and 50% of energy is supplied as fat, protein, and carbohydrate, respectively. The daily intake of cholesterol was about 0.5 mmol.
All operations were done between 08 00 and 09 00 after a 12 hour fast. After opening of the abdomen, A wide range of hexosamine concentrations was observed in the gall stone free subjects and.in the gall stone patients (Figure) between female and male gall stone patients, the mean values being 131 ng/ml and 150 ng/ml, respectively. As shown in Table 3 , the mean concentration of hexosamine in untreated gall stone patients (137 (19) ng/ml) was significantly higher than that of gall stone free subjects (83 (9) ng/ml) (p<002). The hexosamine concentration was similar in the gall stone patients with (138 (21) ng/ml) and without crystals (141 (41) ng/ml) ( Figure) . Ursodeoxycholic acid made gall bladder bile unsaturated in all patients and CDCA in all but one of the patients treated, the mean values being 60% and 74%, respectively ( 18 Therefore, in several human studies and animal experiments, hexosamine, a molecule present only in mucin, has been used as a specific marker for mucin in gall bladder bile.7 [19] [20] [21] The total hexosamine content has been determined by the method of Boas'7 using glucosamine to establish standard curves. In vitro the incorporation of radiolabelled glucosamine has proved to be a quantitative method to measure the rate of gall bladder mucin synthesis and secretion.' 1822 Previous studies have shown that the composition as well as the proportion of the carbohydrates in human gall bladder mucin glycoprotein are equal in patients with cholesterol gall stones and gall stone free controls.122324 In comparative studies of the mucin content in gall bladder bile of patients with and without gall stones it should thus be accurate to assay hexosamine as a specific, quantitative marker of mucin. In the present work, we have improved the hexosamine assay by adding 14C-labelled D-glucosamine as an internal standard to the bile samples, in order to correct for losses during the analytical procedure.
Patients with gall stones displayed significantly higher hexosamine content in gall bladder bile than did gall stone free subjects. Our results thus confirm and extend those of Bouchier et al. ' 
